Seoul National University

The University of Arizona

Gflas Life Sciences, Inc.

Institute for Basic Science

Aict

Arizona State University

Sunghwa Choe

Kenneth A Feldmann

Dong Wook Kim

Jongjin Park

Ricardo Azpiroz

Aiden Y Park

Jin Soo Kim

Jungeun Kim

Sungyong In

Soon Il Kwon

Jung Hak Lim

Je Wook Woo

Ji Young Yoon

Mi Jin Park

Mijin Park

Jung Hyuk Lee

Frans Tax

Sunmee Choi

Junghak Lim

Han Seong Kim

Hyeran Kim

Slki Park

Youngdong Yoo

A pharmaceutical composition for treating cancer, containing a crRNA and an endonuclease as active ingredients is disclosed. The composition can be customized according to the needs of patients or cell types by specifically treating cancer cells on the basis of specific binding properties of DNA and RNA. The nuclease activity of a CRISPR PLUS system, containing both an endonuclease and an exonuclease can be activated by means of the binding between crRNA and a gene specifically found in cancer cells. Therefore, the cancer treatment effect of the composition is more specific than that of other anti-cancer agents that have been developed up till now.

Pharmaceutical composition for treating cancer, containing guide RNA and endonuclease as active ingredients

Enhanced, specific nucleic acid targeting complexes comprising endo and exonuclease activity, and related methods that allow both targeted degradation of specific and/or non-specific nucleic acids in vivo and specific temporal regulation of nuclease activity to prevent off-target activity are disclosed herein. Through practice of the disclosure, nucleic acids, and cells harboring them, such as cancer cells or pathogens, are selectively degraded in vivo.

Sequence-specific in vivo cell targeting

The present disclosure provides novel Cas12a proteins, which cleave target nucleic acids and methods of use thereof.

Compositions and methods for genome engineering with Cas12a proteins

The present disclosure provides compositions and methods for increasing mutation efficiency and homologous recombination rates of site-specific endonucleases. The compositions and methods comprise a chimeric polypeptide comprising a site-specific endonuclease or a domain thereof and a functional moiety. The current inventions relate to functional enhancement of the CRISPR-Cas enzymes. Disclosed herein include possible variants and their intended improvements.

Chimeric genome engineering molecules and methods

The present invention relates to a method of increasing the production efficiency of gene-edited plants, regenerated from plant protoplasts, by use of a Cas protein-guide RNA ribonucleoprotein (RNP). According to the present invention, the method of increasing the production efficiency of gene-edited plants makes it possible to efficiently produce target gene-mutated plants and to minimize the introduction of foreign DNA into plants. Thus, the present invention can be very advantageously used in a wide variety of fields, including agriculture, food and biotechnology.

Method for producing genome-modified plants from plant protoplasts at high efficiency

The present invention relates to method for preparing a plant from a protoplast comprising knocking-out or knocking-in one or more the endogenous gene of the protoplast, and the plant regenerated from a genome-modified protoplast prepared by the above method.

Method for producing whole plants from protoplasts

The present invention relates to novel, polynucleotides isolated from dwarf plants. The dwf4 polynucleotides that encode all, or a portion of, a DWF4 polypeptide, a cytochrome P450 enzyme that mediates multiple steps in synthesis of brassinosteriods. The present invention also relates to isolated polynucleotides that encode regulatory regions of dwf4. Uses of the dwf4 polypeptides and polynucleotides are also disclosed.

DWF4 polynucleotides, polypeptides and uses thereof

DWARF12(DWF12) sequences, mutants and methods of using the same are disclosed. The dwf12 polynucleotides can be used in the production of transgenic plants which display at least one dwf12 mutant phenotype, so that the resulting plants have altered biochemistry, structure or morphology.

[object Object]

The present invention relates to novel, polynucleotides isolated from dwarf plants. The dwf4 polynucleotides that encode all, or a portion of, a DWF4 polypeptide, a cytochrome P450 enzyme that mediates multiple steps in synthesis of brassinosteroids. The present invention also relates to isolated polynucleotides that encode regulatory regions of dwf4. Uses of the dwf4 polypeptides and polynucleotides are also disclosed.

Dwarf7 (dwf7) mutants and polypeptides, as well as methods of using the same, are disclosed. The dwf7 polynucleotides can be used in the production of transgenic plants which display at least one dwf7 phenotype, so that the resulting plants have altered structure or morphology.

Growing community of inventors

Seoul, South Korea

Sunghwa Choe